Mymetics Corp (MYMX)

[Work Harder]

Virosome Vaccines: Articles by Qinjian Zhao

Taken together, these quantitative analytical tools enable more rapid, in-depth, and comprehensive process monitoring, process optimization, and assessment of product consistency and stability.

https://www.expertscape.com/ar/vaccines%2C+virosome/a/Zhao%2C+Qinjian

Merck Research Laboratories, Merck & Co, Inc., West Point, PA 19486, USA. [e-mail]

https://pubmed.ncbi.nlm.nih.gov/21871939/

My passion for biologics: From active sites to life-saving and public health

Qinjian Zhao

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514082/

In 1997 Dr Zhao joined Merck Research Laboratories (West Point, PA) as a Research Fellow and promoted to Senior Investigator and Distinguished Senior Investigator. During his time at Merck, Dr Zhao was involved in the development of a variety of viral and bacterial vaccines: Hepatitis A and B, varicella, influenza, pneumococcal and meningococcal conjugates, and most notably human papilloma virus (HPV). Dr. Zhao played a leading role in the quantitative analysis of vaccine in vitro potency for several vaccines at Merck.

as well as two patents related to the production of Hepatitis B and HPV virus-like-particles with improved properties

including the Industrial Biotechnology Award in 2006, provided by the American Chemical Society to the Team for the development of the quadrivalent HPV vaccine Gardasil®.

To supply the expanding markets for vaccines against hepatitis B and human papilloma virus (HPV), we made the very first ‘Comparability Exercise’ package for HBV (1998-9) given that the regulatory guidelines on Comparability went into effect in the mid-1990s and the second important Comparability Exercise package for Gardasil (2004-6) – the second vaccine (after hepatitis B) ever licensed for preventing an infection that can progress to cancer.

In addition, in the same spirit of Well-Characterized Biologics and Pharmaceuticals, I led efforts in modernizing the in vitro potency assays for hepatitis B and hepatitis A vaccines (Recombivax HB and VAQTA) using monoclonal antibody-based assays – to replace the animal-based potency assays.

Several years after the licensure of Gardasil®, it was gratifying to see a report published in mid-2013 by CDC scientists Markowitz et al that vaccine type HPV (HPV-6, -11, -16 or -18) prevalence among young females aged 14–19 years dropped by ~50% in the US when comparing clinical samples from 4 years (2007–2010) after Gardasil introduction with those before the vaccine introduction (2003–2006), thanks to the advent of an effective vaccine.